The latest price target for IN8bio (NASDAQ:INAB) was reported by HC Wainwright & Co. on February 12, 2025. The analyst firm set a price target for $8.00 expecting INAB to rise to within 12 months (a possible 2973.38% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for IN8bio (NASDAQ:INAB) was provided by HC Wainwright & Co., and IN8bio reiterated their buy rating.

The last upgrade for IN8bio Inc happened on February 11, 2025 when Jones Trading raised their price target to $1.2. Jones Trading previously had a hold for IN8bio Inc.

The last downgrade for IN8bio Inc happened on August 12, 2024 when Jones Trading changed their price target from N/A to N/A for IN8bio Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IN8bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IN8bio was filed on February 12, 2025 so you should expect the next rating to be made available sometime around February 12, 2026.

While ratings are subjective and will change, the latest IN8bio (INAB) rating was a reiterated with a price target of $8.00 to $8.00. The current price IN8bio (INAB) is trading at is $0.26, which is out of the analyst’s predicted range.